FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086146036> ?p ?o ?g. }

• W2086146036 endingPage "346" @default.
• W2086146036 startingPage "345" @default.
• W2086146036 abstract "Forty–six asthmatic patients (males: 20, females: 26; mean age 35 years) with reversible asthma (FEV1≥65%; ≥12% reversibility), airway hyperreactivity (methacholine PC20≤5 mg/ml), and clinical symptoms (bronchodilator use ≥4 days/week) entered this study designed to examine the effects of a primary anti–inflammatory agent (triamcinolone acetonide) compared to a long–acting maintenance bronchodilator (salmeterol), to the combination of both therapeutic agents, and placebo with respect to improvement in clinical symptoms, pulmonary function, and bronchoprotective properties.After initial screening and a 2–week observational period, eligible patients were enrolled into the 6–month treatment arm of the study. Patients were randomized to treatment with either (1) triamcinolone at a dose of 2 puffs four times a day (800 µg/day)×4 weeks followed by a maintenance dosage of 4 puffs twice a day (800 µg/day), (2) salmeterol at 2 puffs twice a day (84 µg/day) and (3) the combination of triamcinolone plus salmeterol twice daily, or placebo. During this treatment phase, methacholine challenge was performed at (2–month) intervals and formal spirometry was done at monthly intervals. Patients continued to keep symptom diaries, medication diaries, and performed peak flow measurements through the 6–month treatment period.Triamcinolone progressively reduced methacholine sensitivity at each time point studied over the 6–month period of treatment. Salmeterol did not result in a significant shift in bronchial hyperresponsiveness. In the group of patients receiving combination therapy, the bronchoprotective effects of triamcinolone were maintained over the 6–month study period (see table 1).Each active treatment resulted in a positive effect on pulmonary function (FEV1). Triamcinolone resulted in a significant increase in FEV1 over baseline at 3 months and 5 months of treatment. Salmeterol also demonstrated a positive effect on FEV1 at 3 months and 5 months of treatment. The combination (triamcinolone plus salmeterol) resulted in an even earlier improvement in FEV1 which was evidenced at 1 month of treatment (p = 0.01) and was sustained at 3 and 5 months of therapy. As expected, placebo treatment did not result in a beneficial effect on FEV1 at any time point. Furthermore, significant between–group differences were observed for both triamcinolone (p = 0.05) and for the combination (triamcinolone plus salmeterol; p = 0.007) when compared with placebo. These findings were corroborated by clinical parameters which demonstrated that all active treatment groups resulted in marked improvement in symptom control (a.m./p.m. symtpoms) and the reduction in the frequency of bronchodilator use. Fewer noctural awakenings were observed in the salmeterol and the combination treatment groups when compared to baseline (table 2).In summary, inhaled steroid treatment (triacinolone acetonide) demonstrated a significant reduction in bronchial hyperresponsiveness (improvement of methacholine PD20 from baseline), a significant effect on parameters of pulmonary function (FEV1 and PEF), and improvement in clinical symptoms. Salmeterol did demonstrate significant improvement in lung function and symptom control. However, salmeterol was not as effective as either triamcinolor or combination therapy in terms of reducing bronchial hyperresponsiveness. An added benefit observed from combining an inhaled steroid with a long–acting bronchodilator was an earlier shift in FEV1 response." @default.
• W2086146036 created "2016-06-24" @default.
• W2086146036 creator A5030806269 @default.
• W2086146036 creator A5031534136 @default.
• W2086146036 creator A5041745213 @default.
• W2086146036 creator A5042711391 @default.
• W2086146036 creator A5045825019 @default.
• W2086146036 creator A5052688805 @default.
• W2086146036 creator A5084787867 @default.
• W2086146036 date "1999-01-01" @default.
• W2086146036 modified "2023-09-27" @default.
• W2086146036 title "Comparison of an Inhaled Corticosteroid (Triamcinolone Acetonide) to a Long–Acting Bronchodilator (Salmeterol), the Combination, and Placebo in Mild–Moderate Adult Asthmatic Patients" @default.
• W2086146036 cites W2077902722 @default.
• W2086146036 cites W2096598461 @default.
• W2086146036 cites W2155345300 @default.
• W2086146036 doi "https://doi.org/10.1159/000024129" @default.
• W2086146036 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10224440" @default.
• W2086146036 hasPublicationYear "1999" @default.
• W2086146036 type Work @default.
• W2086146036 sameAs 2086146036 @default.
• W2086146036 citedByCount "12" @default.
• W2086146036 countsByYear W20861460362021 @default.
• W2086146036 crossrefType "journal-article" @default.
• W2086146036 hasAuthorship W2086146036A5030806269 @default.
• W2086146036 hasAuthorship W2086146036A5031534136 @default.
• W2086146036 hasAuthorship W2086146036A5041745213 @default.
• W2086146036 hasAuthorship W2086146036A5042711391 @default.
• W2086146036 hasAuthorship W2086146036A5045825019 @default.
• W2086146036 hasAuthorship W2086146036A5052688805 @default.
• W2086146036 hasAuthorship W2086146036A5084787867 @default.
• W2086146036 hasConcept C126322002 @default.
• W2086146036 hasConcept C141071460 @default.
• W2086146036 hasConcept C142724271 @default.
• W2086146036 hasConcept C204787440 @default.
• W2086146036 hasConcept C27081682 @default.
• W2086146036 hasConcept C2776042228 @default.
• W2086146036 hasConcept C2776178081 @default.
• W2086146036 hasConcept C2776719499 @default.
• W2086146036 hasConcept C2776804153 @default.
• W2086146036 hasConcept C2776954882 @default.
• W2086146036 hasConcept C2777714996 @default.
• W2086146036 hasConcept C2778903070 @default.
• W2086146036 hasConcept C2780333948 @default.
• W2086146036 hasConcept C2781018748 @default.
• W2086146036 hasConcept C2781260171 @default.
• W2086146036 hasConcept C42219234 @default.
• W2086146036 hasConcept C71924100 @default.
• W2086146036 hasConceptScore W2086146036C126322002 @default.
• W2086146036 hasConceptScore W2086146036C141071460 @default.
• W2086146036 hasConceptScore W2086146036C142724271 @default.
• W2086146036 hasConceptScore W2086146036C204787440 @default.
• W2086146036 hasConceptScore W2086146036C27081682 @default.
• W2086146036 hasConceptScore W2086146036C2776042228 @default.
• W2086146036 hasConceptScore W2086146036C2776178081 @default.
• W2086146036 hasConceptScore W2086146036C2776719499 @default.
• W2086146036 hasConceptScore W2086146036C2776804153 @default.
• W2086146036 hasConceptScore W2086146036C2776954882 @default.
• W2086146036 hasConceptScore W2086146036C2777714996 @default.
• W2086146036 hasConceptScore W2086146036C2778903070 @default.
• W2086146036 hasConceptScore W2086146036C2780333948 @default.
• W2086146036 hasConceptScore W2086146036C2781018748 @default.
• W2086146036 hasConceptScore W2086146036C2781260171 @default.
• W2086146036 hasConceptScore W2086146036C42219234 @default.
• W2086146036 hasConceptScore W2086146036C71924100 @default.
• W2086146036 hasIssue "2-4" @default.
• W2086146036 hasLocation W20861460361 @default.
• W2086146036 hasLocation W20861460362 @default.
• W2086146036 hasOpenAccess W2086146036 @default.
• W2086146036 hasPrimaryLocation W20861460361 @default.
• W2086146036 hasRelatedWork W1974632345 @default.
• W2086146036 hasRelatedWork W1995548154 @default.
• W2086146036 hasRelatedWork W2011384746 @default.
• W2086146036 hasRelatedWork W2086146036 @default.
• W2086146036 hasRelatedWork W2090583799 @default.
• W2086146036 hasRelatedWork W2107458343 @default.
• W2086146036 hasRelatedWork W2116056982 @default.
• W2086146036 hasRelatedWork W2131953615 @default.
• W2086146036 hasRelatedWork W2399767733 @default.
• W2086146036 hasRelatedWork W2882982322 @default.
• W2086146036 hasVolume "118" @default.
• W2086146036 isParatext "false" @default.
• W2086146036 isRetracted "false" @default.
• W2086146036 magId "2086146036" @default.
• W2086146036 workType "article" @default.